GlycoNex Incorporation
4168
Rank in Stocks
#21187
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in... GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Share Price
$0.64017363
Last synced: 2026-11-10
Market Cap
$72.03M
Change (1 day)
0.00%
Change (1 year)
-10.22%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GlycoNex Incorporation (4168)
Category
Healthcare
Operating Margin for GlycoNex Incorporation (4168)
Operating Margin as of November 2026 TTM: -1,342.98%
According to GlycoNex Incorporation's latest financial reports, its current operating margin (TTM) is -1,342.98%. At the end of 2025 the company had an operating margin of -659.81%.
Operating Margin history for GlycoNex Incorporation from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,342.98% | 103.54% |
| 2025 | -659.81% | -60.59% |
| 2024 | -1,674.14% | -83.62% |
| 2023 | -10,222.82% | 1,329.45% |
| 2022 | -715.16% | -77.30% |
| 2021 | -3,150.56% | -91.06% |
| 2020 | -35,240.80% | -4.15% |
| 2019 | -36,766.08% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.89% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about GlycoNex Incorporation's operating margin
What is GlycoNex Incorporation's operating margin?
GlycoNex Incorporation's operating margin is -1,342.98%, as of Nov 2026.
What was GlycoNex Incorporation's operating margin in 2025?
In 2025, GlycoNex Incorporation's operating margin was -659.81%, compared with -1,674.14% in 2024.
How has GlycoNex Incorporation's operating margin changed since 2020?
From 2020 to 2025, GlycoNex Incorporation's operating margin was highest in 2025 (-659.81%) and lowest in 2020 (-35,240.80%).
How does GlycoNex Incorporation's operating margin compare with similar companies?
GlycoNex Incorporation's operating margin (-1,342.98%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.